bimekizumab   Click here for help

GtoPdb Ligand ID: 9411

Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Approved drug Immunopharmacology Ligand
bimekizumab is an approved drug (EMA (2021), FDA (2023))
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EMA (2021)  |  FDA (2023)  |  China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
9878 bimekizumab
Synonyms Click here for help
bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 486
Other databases
GtoPdb PubChem SID 328083513
Search PubMed clinical trials bimekizumab
Search PubMed titles bimekizumab
Search PubMed titles/abstracts bimekizumab